Adaptimmune Clinical Trials full-steam ahead with GSK investment!

03/09/2015 - 3 minutes

Adaptimmune has had exciting results regarding the ongoing battle with Synovial Sarcoma. GSK looks to further invest in the expansion of the clinical trial to include two further cohorts.

Adaptimmune, with a research base in Oxford (UK) and clinical base in Philadelphia (US), has overcome a milestone in their first cohort for clinical stage I/II  T-cell therapy. They have developed a program for T-cell therapeutic candidates engineering various different T-cell receptors (TCR) for a range of cancers including lung, breast and hematologic types.

Their approach works by targeting TCRs of tumor cells that express the NY-ESO-1 antigen. For these, they engineer an artificial T-cell ‘platform,’ which increases the tumor antigen’s sensitivity to the TCR. In doing so, the aim is to restore the efficacy of first line cancer drugs such as ifosfamide alongside (and/or) doxorubicin, which in many patients have been shown to be ineffective. Synovial sarcoma, characterized by tumors forming in the soft connective tissues of joints, expresses the NY-ESO-1 antigen in around 60-70% of cases.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!